Q1. Quality gaps are often discussed in compliance terms, but their business impact can be far reaching. How should organisations better quantify and communicate the true cost of quality failures?
Organisations need to move beyond narrow “cost of compliance” metrics and adopt an enterprise wide Cost of Quality (CoQ) approach that captures both direct and indirect impacts. This includes not only the obvious costs—such as deviation and CAPA management, product or material discards, rework, recalls, and remediation following critical inspection observations—but also the hidden costs that are often far more material.
These include delays in regulatory approvals and time to market due to failed right first time PPQ runs, constrained supply caused by capacity losses, and the opportunity costs of stalled launches or missed market windows. Importantly, companies should explicitly quantify the cost of lost or constrained business resulting from diminished regulator or customer trust, consent decrees, warning letters, or market actions.
Best in class organisations frame quality failures in business language that resonates with senior leadership—linking them to revenue impact, cash flow, working capital, and long term enterprise value. In worst case scenarios, legal exposure, litigation costs, and liabilities related to patient harm must also be considered. Communicating quality performance through this broader financial and risk based lens helps position quality as a strategic value driver rather than a cost center.
“Organizations need to move beyond narrow ‘cost of compliance’ metrics and adopt an enterprise wide Cost of Quality approach that captures both direct and indirect impacts.”
Q2. Emerging modalities such as ATMPs and plasma derived therapies introduce new complexities. What are the most critical quality challenges in these areas, and how should organisations adapt their frameworks?
Speaking from the perspective of plasma derived therapies, one of the most critical quality challenges is managing aging facilities and legacy equipment, which significantly elevate contamination control and operational reliability risks. Across the industry, regulators are increasingly intolerant of these vulnerabilities, particularly where infrastructure no longer aligns with current state of the art expectations.
Organisations must therefore take a risk based, portfolio level approach to capital allocation, prioritising upgrades to critical infrastructure—such as aseptic filling lines and HVAC systems—while simultaneously maintaining healthy plasma economics and supply continuity. This balancing act requires tighter integration between quality, technical operations, finance, and supply planning.
Another growing challenge is the cumulative risk introduced by incremental upstream and downstream process changes aimed at improving yield or efficiency. These changes demand robust, end to end impact assessments to understand combined effects on product purity profiles, viral safety margins, and other critical quality attributes (CQAs).
Leading companies are increasingly leveraging advanced data analytics, predictive trending, and digital twin simulations to anticipate risks before they materialise. These tools enable more proactive decision making, support lifecycle process validation, and strengthen science and risk based justifications with regulators—an approach that is rapidly becoming an industry expectation rather than a differentiator.
Q3. Quality transformation requires strong leadership alignment. How should leadership teams evolve to ensure quality is embedded as a strategic priority rather than a functional obligation?
Sustainable quality transformation starts with visible and consistent leadership ownership. Quality leaders must be embedded as full members of leadership teams and critical project forums at all levels, from site leadership to enterprise governance. This enables joint strategy and goal setting, where quality considerations are integrated up front rather than retrospectively managed.
High performing organisations operate with true cross functional accountability, where each function clearly understands not only its own priorities and constraints, but also the downstream impact of its decisions on product quality and patient safety. In this model, Quality acts as a strategic partner and enabler, not a controlling or gatekeeping function.
Practically, this requires aligned processes, capability building through targeted training, and a small set of meaningful KPIs monitored through tiered governance systems—from shop floor to C suite. Critically, performance management, rewards, and recognition must be linked not only to business or operational results, but also to shared Quality KPIs. This reinforces that quality excellence is how success is defined, owned, and sustained across the organisation.
“Best in class organisations frame quality failures in business language that resonates with senior leadership.”
Q4. Optional Question (Q13). Regulatory inspections are becoming more rigorous and data driven. What are inspectors focusing on most today, and how can organisations better demonstrate control in real operational settings—particularly in areas like contamination control and digital validation?
Across regulatory agencies, inspectors are increasingly focused on whether companies are operating truly in control, not just compliant on paper. Key areas of attention include alignment with state of the art facility and process design, particularly contamination control strategies in line with EU GMP Annex 1 expectations, as well as the robustness of aseptic operations and environmental monitoring programs.
In parallel, there is much deeper scrutiny of digital system validation and data integrity, including governance around computerised systems, lifecycle validation, and the effective use of electronic data to support decision making. Inspectors are also placing strong emphasis on deviation management and CAPA effectiveness, looking for evidence that organisations understand root causes, address systemic issues, and verify sustainable outcomes.
“Companies should explicitly quantify the cost of lost or constrained business resulting from diminished regulator or customer trust.”
To demonstrate control, organisations need to show how quality systems operate in day to day reality: clear process ownership, effective risk management, meaningful trending, and the use of real time data to detect and respond to emerging issues. Companies that can clearly connect their digital tools, contamination control strategies, and quality culture to consistent operational behaviours are best positioned to meet evolving inspection expectations.
